Details of the Drug

General Information of Drug (ID: DM926CH)

Drug Name
CTX130
Indication
Disease Entry ICD 11 Status REF
T-cell lymphoma 2A90 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
DVIY25

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD70 antigen (CD27-L) TTNCIE0 CD70_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease T-cell lymphoma
ICD Disease Classification 2A90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD70 antigen (CD27-L) DTT CD70 1.53E-09 0.76 2.84
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04502446) A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of CRISPR Therapeutics.